2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer’s Disease Brain

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lipid dysregulations have been critically implicated in Alzheimer’s disease (AD) pathology. Chemical analysis of amyloid-β (Aβ) plaque pathology in transgenic AD mouse models has demonstrated alterations in the microenvironment in the direct proximity of Aβ plaque pathology. In mouse studies, differences in lipid patterns linked to structural polymorphism among Aβ pathology, such as diffuse, immature, and mature fibrillary aggregates, have also been reported. To date, no comprehensive analysis of neuronal lipid microenvironment changes in human AD tissue has been performed. Here, for the first time, we leverage matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) through a high-speed and spatial resolution commercial time-of-light instrument, as well as a high-mass-resolution in-house-developed orbitrap system to characterize the lipid microenvironment in postmortem human brain tissue from AD patients carrying Presenilin 1 mutations (PSEN1) that lead to familial forms of AD (fAD). Interrogation of the spatially resolved MSI data on a single Aβ plaque allowed us to verify nearly 40 sphingolipid and phospholipid species from diverse subclasses being enriched and depleted, in relation to the Aβ deposits. This included monosialo-gangliosides (GM), ceramide monohexosides (HexCer), ceramide-1-phosphates (CerP), ceramide phosphoethanolamine conjugates (PE-Cer), sulfatides (ST), as well as phosphatidylinositols (PI), phosphatidylethanolamines (PE), and phosphatidic acid (PA) species (including Lyso-forms). Indeed, many of the sphingolipid species overlap with the species previously seen in transgenic AD mouse models. Interestingly, in comparison to the animal studies, we observed an increased level of localization of PE and PI species containing arachidonic acid (AA). These findings are highly relevant, demonstrating for the first time Aβ plaque pathology-related alteration in the lipid microenvironment in humans. They provide a basis for the development of potential lipid biomarkers for AD characterization and insight into human-specific molecular pathway alterations.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

          We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A Cross-platform Toolkit for Mass Spectrometry and Proteomics

            Mass-spectrometry-based proteomics has become an important component of biological research. Numerous proteomics methods have been developed to identify and quantify the proteins in biological and clinical samples 1 , identify pathways affected by endogenous and exogenous perturbations 2 , and characterize protein complexes 3 . Despite successes, the interpretation of vast proteomics datasets remains a challenge. There have been several calls for improvements and standardization of proteomics data analysis frameworks, as well as for an application-programming interface for proteomics data access 4,5 . In response, we have developed the ProteoWizard Toolkit, a robust set of open-source, software libraries and applications designed to facilitate proteomics research. The libraries implement the first-ever, non-commercial, unified data access interface for proteomics, bridging field-standard open formats and all common vendor formats. In addition, diverse software classes enable rapid development of vendor-agnostic proteomics software. Additionally, ProteoWizard projects and applications, building upon the core libraries, are becoming standard tools for enabling significant proteomics inquiries.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

              Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss Aβ-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E.
                Bookmark

                Author and article information

                Journal
                ACS Chem Neurosci
                ACS Chem Neurosci
                cn
                acncdm
                ACS Chemical Neuroscience
                American Chemical Society
                1948-7193
                01 February 2024
                21 February 2024
                : 15
                : 4
                : 877-888
                Affiliations
                []Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg , Mölndal 43180, Sweden
                []Department of Neuroscience, Physiology and Pharmacology, University College London , London WC1E6BT, United Kingdom
                [§ ]Department of Public Health and Caring Sciences, Uppsala University , Uppsala 75237, Sweden
                []Science for Life Laboratory (SciLife), Uppsala University , Uppsala 75237, Sweden
                []Maastricht MultiModal Molecular Imaging Institute (M4I), Maastricht University , Maastricht 6229 ER, The Netherlands
                [# ]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , Mölndal 43180, Sweden
                []Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , Queen Square, London WC1N 3BG, United Kingdom
                []UK Dementia Research Institute at UCL , London WC1E 6BT, United Kingdom
                []Hong Kong Center for Neurodegenerative Diseases , Clear Water Bay, Hong Kong 999077, China
                []Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison , Madison, Wisconsin 53726, United States
                [†† ]Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University , Paris 75005, France
                [‡‡ ]Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC , Hefei 230001, P. R. China
                [§§ ]Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London , London WC1N 1PJ, United Kingdom
                [∥∥ ]Science for Life Laboratory (SciLife), University of Gothenburg , Gothenburg 40530, Sweden
                Author notes
                [* ]Email: jh@ 123456gu.se .
                Author information
                https://orcid.org/0000-0002-6533-7179
                https://orcid.org/0000-0001-6059-198X
                Article
                10.1021/acschemneuro.4c00006
                10885149
                38299453
                74415135-34e9-4ee1-8f6d-6f87d1447411
                © 2024 The Authors. Published by American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 04 January 2024
                : 09 January 2024
                : 08 January 2024
                Funding
                Funded by: National Institute on Aging, doi 10.13039/100000049;
                Award ID: R01AG078796
                Funded by: Vetenskapsrådet, doi 10.13039/501100004359;
                Award ID: 2019-02397
                Categories
                Research Article
                Custom metadata
                cn4c00006
                cn4c00006

                Neurosciences
                alzheimer’s disease,β-amyloid,plaque pathology,neurolipidomics,mass spectrometry imaging,presenilin 1

                Comments

                Comment on this article